🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for EGFR Gene Mutation

Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial) NCT07073365Phase 21 site📍 Busan Pusan National University Hospital · Tests: Local Therapy (Surgery or Radiotherapy) Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma NCT05528458Phase 21 site📍 Seoul Samsung Medical Center · Tests: Osimertinib 80Mg Tab TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases NCT05948813Phase 21 site📍 Beijing TYK Medicines, Inc · Tests: TY-9591, Osimertinib A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation NCT06102928NA1 site📍 Kunming Kunming Medical University · Tests: Combined therapy of anlotinib and aumolertinib IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC NCT05994131Phase 1, Phase 21 site📍 Shanghai InxMed (Shanghai) Co., Ltd. · Tests: IN10018, Furmonertinib A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy NCT04557462Phase 3161 sites📍 Glendale📍 San Diego📍 San Dimas Novartis Pharmaceuticals · Tests: LNP023 A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases NCT05033691NA1 site📍 Jerusalem Hadassah Medical Organization · Tests: Stereotactic surgery Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. NCT06238882NA1 site📍 Mexico City Instituto Nacional de Cancerologia de Mexico · Tests: Nitroglycerin A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation NCT07231068Phase 1, Phase 25 sites📍 Beijing📍 Beijing📍 Guangzhou Henan Genuine Biotech Co., Ltd. · Tests: Dositinib mesylate tablets Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases NCT07304739Phase 23 sites📍 Cangzhou📍 Tianjin📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Furmonertinib, Intrathecal chemotherapy, Stereotactic radiotherapy Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib NCT04486833Phase 1, Phase 210 sites📍 Los Angeles📍 Lone Tree📍 Urbana Genprex, Inc. · Tests: quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis NCT06643000NA2 sites📍 Zhengzhou📍 Zhengzhou Henan Cancer Hospital · Tests: furmonertinib A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer NCT06631989Phase 1, Phase 212 sites📍 Hefei📍 Beijing📍 Guangzhou Wayshine Biopharm, Inc. · Tests: WSD0922-FU Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients NCT06659458n/a1 site📍 Baton Rouge Our Lady of the Lake Hospital · Tests: blood draw, Gene sequencing Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge NCT04335292Phase 210 sites📍 Vancouver📍 Vancouver📍 Brampton Mark Vincent · Tests: Osimertinib First-Line, Platinum + Pemetrexed Chemotherapy Second-Line, Osimertinib Third-Line Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells NCT06186401Phase 11 site📍 San Francisco Hideho Okada, MD, PhD · Tests: E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical rese… Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) NCT05382728Phase 32 sites📍 Changsha📍 Shanghai TYK Medicines, Inc · Tests: TY-9591, placebo Osimertinib, Osimertinib, placebo TY-9591 HEAT Trial (HER2 Antibody Therapy With Lutetium-177) NCT06824155EARLY Phase 15 sites📍 Kingswood📍 Macquarie Park📍 Wollongong Radiopharm Theranostics, Ltd · Tests: 177Lu-RAD202 Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression NCT06269211Phase 22 sites📍 Guangzhou📍 Shanghai Ruijin Hospital · Tests: Toripalimab First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) NCT05099172Phase 1, Phase 294 sites📍 Gilbert📍 Duarte📍 Atlanta Bayer · Tests: BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2, BAY2927088_formulation B_3 Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion NCT06247826NA18 sites📍 Bordeaux📍 Brest📍 Créteil Groupe Francais De Pneumo-Cancerologie · Tests: Blood sampling Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations NCT07185997Phase 3139 sites📍 Fullerton📍 Los Angeles📍 Orange ArriVent BioPharma, Inc. · Tests: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC NCT06951464Phase 21 site📍 Chengdu Sichuan University · Tests: BL-B01D1, Almonertinib Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration NCT05315700Phase 1, Phase 242 sites📍 Duarte📍 Huntington Beach📍 Irvine ORIC Pharmaceuticals · Tests: ORIC-114, Chemotherapy drug Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations NCT06674343Phase 31 site📍 Beijing Peking Union Medical College Hospital · Tests: Furmonertinib A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases NCT06970639Phase 31 site📍 Guangdong Allist Pharmaceuticals, Inc. · Tests: Furmonertinib Mesilate Tablets, Carboplatin Injection, Cisplatin for injection, Pemetrexed Disodium for Injection, Osim… Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer NCT06755684Phase 21 site📍 Shanghai Peng Zhang · Tests: Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases NCT05768490Phase 31 site📍 Guangdong Sun Yat-sen University · Tests: brain radiotherapy, Almonertinib A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer NCT04951635Phase 31 site📍 Ji'nan Jiangsu Hansoh Pharmaceutical Co., Ltd. · Tests: Almonertinib, Placebo Almonertinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy